MX2009014178A - Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa. - Google Patents

Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.

Info

Publication number
MX2009014178A
MX2009014178A MX2009014178A MX2009014178A MX2009014178A MX 2009014178 A MX2009014178 A MX 2009014178A MX 2009014178 A MX2009014178 A MX 2009014178A MX 2009014178 A MX2009014178 A MX 2009014178A MX 2009014178 A MX2009014178 A MX 2009014178A
Authority
MX
Mexico
Prior art keywords
composition
alginic acid
microparticles
controlled release
intravenous administration
Prior art date
Application number
MX2009014178A
Other languages
English (en)
Inventor
Gamon Salvador Grancha
Sune Negre Josep Maria
Tico Grau Josep Ramon
Nardi Racart Anna
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40793335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009014178(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2009014178A publication Critical patent/MX2009014178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere una composición biocompatible que comprende micropartículas del ácido algínico o sus sales y un principio activo. Maás en particular, la presente invención se refiere a micropartículas para la encapsulación de un principio activo que va a ser administrado por vía intravenosa a un paciente que lo necesite. Dichas micropartículas que tienen una combinación de tamaño adecuada para lograr un incremento de la vida media o permanencia del principio activo en sangre, con una baja captación hepática y un rápido aclaramiento celular cuando son administradas por vía intravenosa.
MX2009014178A 2008-12-23 2009-12-21 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa. MX2009014178A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200803671A ES2319158B1 (es) 2008-12-23 2008-12-23 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.

Publications (1)

Publication Number Publication Date
MX2009014178A true MX2009014178A (es) 2010-06-30

Family

ID=40793335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014178A MX2009014178A (es) 2008-12-23 2009-12-21 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.

Country Status (17)

Country Link
US (1) US7931916B2 (es)
EP (1) EP2201940B1 (es)
JP (2) JP5297994B2 (es)
CN (1) CN101757631B (es)
AR (1) AR074820A1 (es)
AU (1) AU2009248454B2 (es)
BR (1) BRPI0906284A2 (es)
CA (1) CA2688047C (es)
CL (1) CL2009002204A1 (es)
ES (2) ES2319158B1 (es)
HK (1) HK1141451A1 (es)
HU (1) HUE028485T2 (es)
MX (1) MX2009014178A (es)
NZ (1) NZ582166A (es)
PL (1) PL2201940T3 (es)
RU (1) RU2476235C2 (es)
UY (1) UY32354A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102429862B (zh) 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
RU2519158C1 (ru) * 2013-03-28 2014-06-10 Федеральное государственное бюджетное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения Российской Федерации (ФГБУ "СарНИИТО" Минздрава России) Биодеградируемое раневое покрытие и способ получения биодеградируемого раневого покрытия
CN104888226A (zh) * 2014-03-06 2015-09-09 中国科学院大连化学物理研究所 一种蛋白质和/或多肽类物质的制剂
CN107690333B (zh) * 2015-06-10 2021-12-17 赢创运营有限公司 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法
EP3411022B1 (en) 2016-02-01 2021-09-15 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
WO2018144556A1 (en) * 2017-01-31 2018-08-09 Georgia Tech Research Corporation Compositions and methods for inhibiting shear-induced platelet accumulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518046A (en) 1982-06-21 1985-05-21 Deere & Company Multiple implement hitch and transport
WO1991009119A1 (en) * 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
RU2071765C1 (ru) * 1994-07-14 1997-01-20 Российский научно-исследовательский институт гематологии и трансфузиологии Способ получения липосом
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JPH11130698A (ja) 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7381415B2 (en) * 2002-03-29 2008-06-03 Shiseido Co., Ltd. Composite powder and cosmetic containing the same
EP1501541A1 (en) * 2002-04-30 2005-02-02 Canadian Blood Services Encapsulated cells to elicit immune responses
WO2006028996A2 (en) 2004-09-03 2006-03-16 Trustees Of Tufts College Emulsan-alginate microspheres and methods of use thereof
JP2008539259A (ja) * 2005-04-27 2008-11-13 バクスター・インターナショナル・インコーポレイテッド 表面を修飾した微粒子およびその形成方法および使用
NZ567216A (en) 2005-10-21 2010-03-26 Living Cell Products Pty Ltd Encapsulation system
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
US8231907B2 (en) * 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
EP2061509A2 (en) 2006-08-14 2009-05-27 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
EP1958622A1 (en) * 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
US9114127B2 (en) 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
DE202008009270U1 (de) 2008-07-10 2009-11-12 Steelcase Werndl Ag Wandförmiges Standmöbel
EP2159523B1 (en) 2008-08-29 2018-08-01 Electrolux Home Products Corporation N.V. Refrigeration equipment and console system for use therein

Also Published As

Publication number Publication date
US7931916B2 (en) 2011-04-26
UY32354A (es) 2010-07-30
ES2319158A1 (es) 2009-05-04
AU2009248454B2 (en) 2011-07-28
RU2476235C2 (ru) 2013-02-27
JP5698296B2 (ja) 2015-04-08
CL2009002204A1 (es) 2010-05-07
NZ582166A (en) 2011-06-30
AR074820A1 (es) 2011-02-16
CA2688047C (en) 2012-08-21
HK1141451A1 (en) 2010-11-12
ES2563632T3 (es) 2016-03-15
PL2201940T3 (pl) 2016-06-30
EP2201940A1 (en) 2010-06-30
JP2010150257A (ja) 2010-07-08
EP2201940B1 (en) 2016-02-24
JP2013136636A (ja) 2013-07-11
CA2688047A1 (en) 2010-06-23
AU2009248454A1 (en) 2010-07-08
RU2009147838A (ru) 2011-06-27
CN101757631B (zh) 2013-02-27
BRPI0906284A2 (pt) 2013-07-30
CN101757631A (zh) 2010-06-30
ES2319158B1 (es) 2010-01-26
HUE028485T2 (en) 2016-12-28
US20100159017A1 (en) 2010-06-24
JP5297994B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
GB2491328A (en) Immediate/delayed drug delivery
GB2491775A (en) Pulsatile drug release
GB2491327A (en) Delayed prolonged drug delivery
MX2009014178A (es) Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
PH12014502460A1 (en) Lyophilised and aqueos anti-cd40 antibody formulations
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
MX2011009174A (es) Formulaciones de insulina para captacion rapida.
WO2013123492A3 (en) Glucose-responsive microgels for closed loop insulin delivery
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
WO2012073170A3 (fr) Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées
WO2012024293A3 (en) Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
WO2012106058A3 (en) Animal treatments
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
SG195192A1 (en) Non-peptidyl polymer-insulin multimer and method for producing the same
AR082806A1 (es) Composicion farmaceutica estable
WO2010064817A3 (ko) 신규 쿠마린계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
IN2012CH05549A (es)
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
Announces Andexanet-α shows promise as sustained antidote to apixaban

Legal Events

Date Code Title Description
FG Grant or registration